PFIZER INC reported its experimental 25-valent pneumococcal vaccine produced antibody levels 15 times higher than its current shot in a mid-stage trial. The 25vPnC candidate outperformed Prevnar 20 across all target strains in healthy infants. This advance matters because 25vPnC could protect against 90% of disease-causing strains in children under five, exceeding current immunizations.

Superior Antibody Response in Infants